SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a fresh 52-week high amid anticipation of its Q3 earnings report and continued optimism around BRIUMVIs growth. Traders debate whether the rally reflects earnings expectations and business momentum or buyout and short-covering speculation; a potential acquisition remains unconfirmed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure amid approaching midterms, with traders focusing on reports that Trump canceled campaign rallies and on expectations of Democratic gains that could bring greater scrutiny of his administration. Bearish posts dominate, while some bulls argue the selloff could reverse after the election.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

A sharp pullback in ALAB has traders focused on whether it can hold key chart support ahead of earnings, with the report and guidance viewed as a potential catalyst. Bulls call the drop an opportunity amid continued AI data-center demand, while bears point to the stocks rich valuation and concerns about a broader AI-trade slowdown.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines results and weaker outlook have focused attention on soaring jet-fuel costs, which are squeezing margins despite strong revenue and travel demand. Traders are divided between concerns about losses and the airlines heavy debt burden, and hopes that lower fuel prices and premium demand could support a recovery.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Federal cannabis rescheduling is the dominant topic, with traders focused on procedural delays in the DEA process and uncertainty around when a Schedule III decision could arrive. Some see the delays and resulting weakness as an overreaction and a potential buying opportunity, while others are frustrated that the catalyst remains uncertain and has not supported the shares.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

Rising concern about AI-enabled cyberattacks is fueling discussion of SentinelOnes cybersecurity opportunity, while traders also emphasize its lower valuation than peers and speculate about a potential takeover. Those bullish themes are offset by worries about growth, recent financing-related dilution, and weakness across cybersecurity stocks; no acquisition is confirmed.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinears strong quarterly results and higher outlook, driven by accelerating AI data-center optics demand, are the main focus. Traders are divided as the shares sell off despite the upbeat report, with some buying the dip while others point to volatility and weak cash generation as risks.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTXs sharp drop is drawing dip-buying and rebound speculation, while bearish traders warn that further weakness in Bitcoin or Strategy (MSTR) could deepen losses. The debate also centers on the funds 2x daily leverage and volatility decay, which can erode returns when held through choppy markets.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors approaching FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, the revised upper-limb data, and recent commercial job postings. Some see FDA flexibility and INOs approval as encouraging signals, while others caution that hiring is not proof of approval and cite the prior AdCom concerns and efficacy debate.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo shares are under pressure after MaxLinear outlined plans to compete for a share of the 1.6T cable market that Credo currently dominates. Traders debate whether the threat is meaningful given its timeline and expanding demand, while broader AI-sector weakness and insider selling add to bearish sentiment; others view the decline as an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STRO Stock Plummets 15% —  What Drove The Selloff?

Equity

H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004 by the company. 


Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.read more...

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.read more...

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial

Truist Financial raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Monday...

Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High  - Still a Buy?

Sutro Biopharma (NASDAQ:STRO) Sets New 52-Week High - Still a Buy...

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating

Mizuho upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Thursday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Neutral Sentiment

<ul class="summary-bullets"><li>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.</li><li>A fuller update is planned for the first half of 2027.</li><li>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028.</li></ul><p>Shares of Sutro Biopharma (STRO) fell 15% on Wednesday after the company reported second-quarter results and an early look at its lead experimental cancer drug STRO-004.</p><p>H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004. The firm said investors had hoped for a more complete readout or enough patient-level information to judge the strength and staying power of the responses. Wainwright views the reaction as overdone because the data remain early, while the drug already shows clearer safety advantages over approved tissue-factor antibody-drug conjugates. The firm reiterated its ‘Buy’ rating and $50 price target. The price target implies a potential upside of 135% from the stock's closing price on Wednesday.&nbsp;</p><h2 class="st-heading-2">Early Signs Of Activity With Good Tolerability</h2><p>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers. The drug was generally well tolerated, with dose-limiting side effects appearing only at the highest dose tested and leading to reductions rather than dropouts, the company said.</p><p>The overall rate of patients stopping treatment because of side effects was low at 6%. Enrollment of the first dose groups moved faster than expected, and the company is still refining the best dose.</p><p>A fuller update is planned for the first half of 2027. CEO Jane Chung said the early STRO-004 findings strengthen confidence in the drug’s potential to deliver meaningful benefit and open the door to combinations.</p><h2 class="st-heading-2">Pipeline Progress And Solid Cash Position</h2><p>Beyond STRO-004, Sutro expects to start clinical testing of STRO-006, another antibody-drug conjugate for solid tumors, in the third quarter of 2026. Its wholly owned STRO-227 program remains on track for an investigational new drug application later this year and offers a longer-term growth path for the company’s platform.</p><p>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028. Second-quarter revenue was $9.8 million, mainly from its collaboration with Japan's Astellas Pharma, while the net loss was $38.5 million.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around STRO stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume remained at ‘high’ levels.</p><p>A Stocktwits user expressed optimism about the company’s pipeline.</p><p><stembedurl>https://www.stocktwits.com/KY3000/message/661632677</stembedurl></p><p><a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has gained 84% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-in-focus-as-candel-nears-year-end-bla-filing-for-prostate-cancer-drug-eyes-10-16-b-opportunity/cZo8g37RJWo">CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Sutro Biopharma logo is seen displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.A fuller update is planned for the first 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$STRO I like that they have cash into 2028, 

STRO specializes in Antibody-Drug Conjugates (ADCs), one of oncology's hottest sectors. They possess a robust balance sheet with $164.3M in cash, funding operations into mid-2028.

Zechs Merquise

$STRO i have been trickling in here 50 shares at a time.  600 now.  But i am starting to wonder what’s going on.  I assume in the absence of catalysts they are just selling for tax loss with shorts joining the party.  Please chime in if you have more info or insights. GL!

Awsi Obutu

$STRO sell the company, astellas took 2nd target into clinic, 002 given to aml charity, vaxcyte on the eve of approval, STRO is validated?

Feed

News

Sentiment

Earnings

Fundamentals

Info

STRO Sutro Biopharma Inc

Fundamentals

Latest STRO News